Congress funds cord blood banking—a quiet win for transplant patients
H.R. 5160 — Stem Cell Therapeutic and Research Reauthorization Act of 2025 · Filed by Chris Smith (R-NJ) · 21 cosponsors · Introduced Sep 4, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reauthorizes federal funding for the C.W. Bill Young Cell Transplantation Program, which maintains a national inventory of cord blood units for medical transplants. It appropriates $31 million for 2026 and $33 million annually for 2027–2031, updates quality standards for stored cord blood, gives the Secretary of Health and Human Services authority to manage inventory based on scientific evidence, and allows transfer of units between qualified banks if one closes or fails to meet standards.
Why we flagged it
The bill's core function is straightforward: it reauthorizes and funds a federal cord blood banking program, updates its operational standards, and clarifies the Secretary's management authority. This is routine public-health legislation with no hidden mechanisms or narrow beneficiaries.
What the text implies
- Expanded Secretary discretion to manage inventory 'on Sec.'s own initiative' may allow de facto prioritization of certain genetic profiles or clinical uses without explicit statutory criteria, though framed as science-based.
- Authority to transfer cord blood units between banks if one becomes non-operational could consolidate inventory management among fewer providers, potentially affecting smaller cord blood banks' operational viability.
The full analysis lists 3 implications of this text.
Who stands to gain
Cord blood banking organizations and qualified cord blood banks (contract holders); Biopharmaceutical companies developing cell therapies (indirect: expanded inventory supports researc